BIOMAT Database Logo BIOMAT Database Logo

Sensitivity of Ph 1 + CFU-GM to human recombinant interferon alpha and gamma alone and in combination. 1988

G Visani, and D Russo, and D Damiani, and S Rizzi, and M R Motta, and R M Lemoli, and C Poluzzi, and R Fanin, and E Zuffa, and P Tosi
Institute of Hematology L. e A. Seagnoli, Bologna University, Italy.

The in vitro effect of human recombinant interferon alpha (IFN) alone and in combination were studied on granulomonocytic colony forming units (CFU-GM) from the peripheral blood of 10 Ph 1+ chronic myeloid leukemia (CML) patients and from the marrow of 5 normal or non-leukemic subjects. alpha- and gamma-IFN alone determined a slight inhibition on colony growth with a preferential effect on "pure" macrophagic colonies. At maximum concentration (10(4) U/ml) leukemic colony inhibition was 46 +/- 34% for alpha IFN and 43 +/- 19% for gamma IFN. Culture growth with alpha + gamma IFN in combination were significantly inhibited (up to 96 +/- 4%) with a concentration-related effect. Similar results were obtained with normal CFU-GM. The synergism that was found in vitro is probably relevant for the in vivo therapeutic effects of these compounds in CML and suggest that the combination is worth testing in vivo.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D010677 Philadelphia Chromosome An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE). Ph1 Chromosome,Ph 1 Chromosome,1 Chromosomes, Ph,Chromosome, Ph 1,Chromosome, Ph1,Chromosome, Philadelphia,Chromosomes, Ph 1,Chromosomes, Ph1,Ph 1 Chromosomes,Ph1 Chromosomes
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006098 Granulocytes Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS. Granulocyte
D006131 Growth Inhibitors Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth ( Cell Growth Inhibitor,Cell Growth Inhibitors,Growth Inhibitor,Growth Inhibitor, Cell,Growth Inhibitors, Cell,Inhibitor, Cell Growth,Inhibitor, Growth,Inhibitors, Cell Growth,Inhibitors, Growth
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G Visani, and D Russo, and D Damiani, and S Rizzi, and M R Motta, and R M Lemoli, and C Poluzzi, and R Fanin, and E Zuffa, and P Tosi
Effect of recombinant human interferon gamma and interleukin 2 on CFU-GM.
June 1986, Behring Institute Mitteilungen,
G Visani, and D Russo, and D Damiani, and S Rizzi, and M R Motta, and R M Lemoli, and C Poluzzi, and R Fanin, and E Zuffa, and P Tosi
Effect of alpha and gamma interferon on CFU-GM.
January 1986, Blood,
G Visani, and D Russo, and D Damiani, and S Rizzi, and M R Motta, and R M Lemoli, and C Poluzzi, and R Fanin, and E Zuffa, and P Tosi
Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM).
October 1988, Blood,
G Visani, and D Russo, and D Damiani, and S Rizzi, and M R Motta, and R M Lemoli, and C Poluzzi, and R Fanin, and E Zuffa, and P Tosi
The comparison of 2-chlorodeoxyadenosine (2-Cd A) in combination with interferon alpha (IFN alpha) or interferon gamma (IFN gamma) on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic blasts in (CFU-L) in vitro cultures.
March 1996, Leukemia & lymphoma,
G Visani, and D Russo, and D Damiani, and S Rizzi, and M R Motta, and R M Lemoli, and C Poluzzi, and R Fanin, and E Zuffa, and P Tosi
Recombinant interferon-alpha-2C in chronic myelogenous leukaemia: relationship of sensitivity of committed haematopoietic precursor cells in vitro (BFU-E, CFU-GM, CFU-Meg) and clinical response.
January 1990, Leukemia research,
G Visani, and D Russo, and D Damiani, and S Rizzi, and M R Motta, and R M Lemoli, and C Poluzzi, and R Fanin, and E Zuffa, and P Tosi
Studies on sensitivity of human GM-CFU and L-CFU to hyperthermic killing in vitro.
January 1989, Leukemia research,
G Visani, and D Russo, and D Damiani, and S Rizzi, and M R Motta, and R M Lemoli, and C Poluzzi, and R Fanin, and E Zuffa, and P Tosi
The synergistic effect of human recombinant interferon-alpha 2a in combination with interferon-gamma and the induction of interferon-alpha 2a receptor by interferon-gamma.
May 1989, Journal of pharmacobio-dynamics,
G Visani, and D Russo, and D Damiani, and S Rizzi, and M R Motta, and R M Lemoli, and C Poluzzi, and R Fanin, and E Zuffa, and P Tosi
Effects of human alpha-interferon on granulocyte-macrophage progenitor cells (CFU-GM) in vitro.
March 1988, Blut,
G Visani, and D Russo, and D Damiani, and S Rizzi, and M R Motta, and R M Lemoli, and C Poluzzi, and R Fanin, and E Zuffa, and P Tosi
In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
December 1995, Experimental hematology,
G Visani, and D Russo, and D Damiani, and S Rizzi, and M R Motta, and R M Lemoli, and C Poluzzi, and R Fanin, and E Zuffa, and P Tosi
Differential in vitro effects of recombinant alpha-interferon and recombinant gamma-interferon alone or in combination on the expression of melanoma-associated surface antigens.
April 1988, Journal of biological response modifiers,
Copied contents to your clipboard!